What's the problem with generic antiepileptic drugs?: a call to action.
Berg
Michel J
MJ
D000927:Anticonvulsants / Q000009:adverse effects* / Q000191:economics / Q000493:pharmacokinetics*; D003362:Cost-Benefit Analysis; D017277:Drug Approval / Q000706:statistics & numerical data; D016568:Drugs, Generic / Q000009:adverse effects* / Q000191:economics / Q000493:pharmacokinetics*; D004827:Epilepsy / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D011358:Product Surveillance, Postmarketing / Q000379:methods*; D018570:Risk Assessment; D055502:Secondary Prevention; D013810:Therapeutic Equivalency; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration / Q000592:standards / Q000706:statistics & numerical data
D000927:Anticonvulsants; D016568:Drugs, Generic